Efficacy/tolerability of 2nd-line aflibercept vs bev beyond PD
How would you compare the efficacy of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
How would you compare the side effects and tolerabilty of aflibercept to the use of bevacizumab on disease progression in the second-line setting?
Bennouna J et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37. Abstract
Ferry D et al. On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: Updated efficacy results from the VELOUR study. Proc ASCO 2013;Abstract 3573.
Gaya A et al. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 2012;38(5):484-93. Abstract
Ruff P et al. Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. Proc ASCO 2013;Abstract 3574.
Van Cutsem E et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. Abstract